OTCMKTS:MKGAFMerck KGaA Stock Price, Forecast & News

$108.20

-7.81 (-6.73 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$108.20

Now: $108.20▼

$116.80

50-Day Range

$97.55

MA: $111.34▼

$119.65

52-Week Range

$82.00

Now: $108.20▼

$134.00

Volume20 shs

Average Volume1,325 shs

Market Capitalization$13.98 billion

P/E Ratio18.30

Dividend YieldN/A

Beta0.8

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Merck KGaA.

2.3 Community Rank

Outperform Votes
Merck KGaA has received 169 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck KGaA has received 201 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck KGaA has received 54.32% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote “Outperform” if you believe MKGAF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MKGAF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Merck KGaA does not currently pay a dividend.
Dividend Growth
Merck KGaA does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck KGaA insiders have not sold or bought any company stock.

1.3 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Merck KGaA is 18.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck KGaA is 18.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.26.
Price to Book Value per Share Ratio
Merck KGaA has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.71 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:MKGAF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.merckgroup.com

Phone49-61-517-20

Debt

Debt-to-Equity Ratio0.48

Current Ratio0.76

Quick Ratio0.48

Price-To-Earnings

Trailing P/E Ratio18.30

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$18.09 billion

Price / Sales0.77

Cash Flow$37.83 per share

Price / Cash Flow2.86

Book Value$155.24 per share

Price / Book0.70

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$1.48 billion

Net Margins22.17%

Return on Equity12.76%

Return on Assets5.82%

Miscellaneous

Employees57,071

Outstanding Shares129,242,000

Market Cap$13.98 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableNot Optionable

Receive MKGAF News and Ratings via Email

Sign-up to receive the latest news and ratings for MKGAF and its competitors with MarketBeat's FREE daily newsletter.

Merck KGaA (OTCMKTS:MKGAF) Frequently Asked Questions

How has Merck KGaA's stock been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at $111.2250 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MKGAF shares have decreased by 2.7% and is now trading at $108.20. View which stocks have been most impacted by Coronavirus.

When is Merck KGaA's next earnings date?

Merck KGaA is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Merck KGaA.

How were Merck KGaA's earnings last quarter?

Merck KGaA (OTCMKTS:MKGAF) posted its quarterly earnings results on Thursday, May, 14th. The company reported $1.66 earnings per share (EPS) for the quarter. The company earned $4.82 billion during the quarter. Merck KGaA had a return on equity of 12.76% and a net margin of 22.17%. View Merck KGaA's earnings history.

Has Merck KGaA been receiving favorable news coverage?

Media headlines about MKGAF stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck KGaA earned a news impact score of -3.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutMerck KGaA.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Beigene (BGNE), Sarepta Therapeutics (SRPT) and Catalent (CTLT). View all competitors.

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:

Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the OTCMKTS under the ticker symbol "MKGAF."

How do I buy shares of Merck KGaA?

Shares of MKGAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck KGaA's stock price today?

One share of MKGAF stock can currently be purchased for approximately $108.20.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $13.98 billion and generates $18.09 billion in revenue each year. Merck KGaA employs 57,071 workers across the globe.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, Darmstadt 2M, 64293. The company can be reached via phone at 49-61-517-20 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

OTCMKTS:MKGAFMerck KGaA Stock Price, Forecast & News

Adding

Adding

Adding Merck KGaA

Beat the Market (BTM) Rank™